Key Highlights
- John Hayslip, M.D., appointed as Chief Medical Officer of Verastem Oncology, succeeding Louis J. Denis, M.D.
- Dr. Hayslip brings extensive experience from I-MAB Biopharma and Nektar Therapeutics.
- Focus on advancing clinical programs for RAS/MAPK pathway-driven cancers.
Source: Business Wire
Notable Quotes
- “John is a recognized leader in oncology with broad expertise across cancer research and development,” – Dan Paterson, President and CEO at Verastem Oncology
- “I am excited to join Verastem Oncology and look forward to working with the team to potentially bring a much-needed new treatment option to patients,” – John Hayslip, M.D., Chief Medical Officer at Verastem Oncology
SoHC's Take
The appointment of Dr. John Hayslip as Chief Medical Officer marks a significant milestone for Verastem Oncology as it underscores their commitment to leadership and innovation in cancer research, particularly in targeting RAS/MAPK pathway-driven cancers. Dr. Hayslip’s rich background in clinical research and development combined with his recent roles at I-MAB Biopharma and Nektar Therapeutics positions him uniquely to lead Verastem’s ambitious medical strategies. This strategic hire is poised to enhance Verastem Oncology’s focus on developing novel therapies that could improve outcomes for patients battling cancer.
